Pomerantz Law Firm Launches Investigation into Sensus Healthcare, Inc. Investor Claims

Pomerantz Law Firm Investigates Sensus Healthcare, Inc.

On September 28, 2025, Pomerantz LLP announced that it is conducting an investigation into investor claims related to Sensus Healthcare, Inc., trading under the NASDAQ symbol SRTS. This inquiry aims to determine whether the company and some of its officers or directors were involved in securities fraud or any unlawful business practices that may have harmed investors' interests.

The impetus for this investigation arises from Sensus's recent financial disclosures. In its second-quarter report dated August 7, 2025, the company revealed a GAAP earnings-per-share figure of -$0.06. This result fell short of analysts’ expectations by $0.09. Moreover, Sensus reported revenue of $7.3 million, reflecting a decrease of 20.7% compared to the same quarter in the previous year while missing estimates by $2 million. The company attributed this decline in revenue mainly to a reduced number of units sold to a significant customer, an offset to this downturn being growth in recurring revenue from Fair Deal Agreements.

Following this disappointing financial report, shares of Sensus experienced a sharp decline, plummeting by $1.89, which is a staggering 35.32%, to close at $3.46 per share on August 8, 2025. This steep drop exemplifies the impact that unexpected financial results can have on investor confidence and company valuations.

Pomerantz LLP, which has a notable reputation in the field of corporate, securities, and antitrust class action litigation, has dedicated itself for over 85 years to fighting for the rights of victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. With offices spread across New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm continues its efforts to hold corporations accountable to their investors.

Through this particular investigation, Pomerantz aims to ascertain if the actions of Sensus Healthcare and its management merit legal scrutiny. Investors holding shares in the company during the relevant period are advised to contact Danielle Peyton at Pomerantz LLP for further engagement in this matter. Potential affected investors can reach out via email at [email protected] or by phone at 646-581-9980, extension 7980, for more information about joining a potential class action lawsuit.

The firm's founder, the late Abraham L. Pomerantz, is often referred to as the dean of the class action bar due to his pioneering efforts in securities class actions. Today, Pomerantz continues to uphold this legacy, having successfully obtained various multimillion-dollar settlements on behalf of its clients.

This situation serves as a reminder to investors about the volatility and risks associated with the stock market, particularly when individual company performances do not align with market expectations. As the investigation progresses, more information will likely emerge about Sensus's practices and the potential implications for its stakeholders.

For those interested in staying informed about this matter and similar cases, Pomerantz LLP regularly publishes updates and insights through its official website at www.pomlaw.com. Interested parties are encouraged to follow their announcements as they navigate this complex legal landscape.